Who is sponsoring NCT04959760?

NCT04959760 is sponsored by Abbott Rapid Diagnostics Jena GmbH.

What drugs are being tested in NCT04959760?

Interventions in NCT04959760: The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2..

What condition does NCT04959760 study?

NCT04959760 studies COVID-19 Respiratory Infection.

Is NCT04959760 still recruiting?

NCT04959760 is currently completed. Last updated 9 May 2022.

Last reviewed 2022-05-09 · How we verify

NCT04959760

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BinaxNow COVID-19 IgG Rapid Test Device and Antibody Self Test

Completed NA Last updated 9 May 2022

What this trial tests

NA trial testing The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2. in COVID-19 Respiratory Infection in 263 participants. Completed in 20 January 2022.

Timeline

3 June 2021

Primary endpoint
20 January 2022

20 January 2022

Quick facts

Lead sponsor	Abbott Rapid Diagnostics Jena GmbH
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	263
Start date	3 June 2021
Primary completion	20 January 2022
Estimated completion	20 January 2022
Sites	5 locations across United States

Drugs / interventions tested

The BinaxNOW™ Antibody Tests measure IgG antibodies against SARS-CoV-2.

Conditions studied

COVID-19 Respiratory Infection — all drugs for COVID-19 Respiratory Infection →

Sponsor

Abbott Rapid Diagnostics Jena GmbH

Who can join

18 and older, any sex, with COVID-19 Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Performance evaluation of the BinaxNOW™ COVID-19 IgG Rapid Test Device (Professional Use) and with BinaxNOW™ COVID-19 Antibody Self Test wehn used with fingerstick capillary whole blood and plasma samples. The BinaxNOW™ Antibody Tests are lateral flow tests that measure SARS-CoV-2 IgG antibodies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for COVID-19 Respiratory Infection

Currently open trials in the same condition.

NCT06950177 — Pancoronavirus Vaccine Study in Healthy Adults · Phase 1 · active not recruiting
NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
NCT05689034 — Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 · Phase 2, PHASE3 · recruiting
NCT05562505 — Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure · NA · recruiting

Other Abbott Rapid Diagnostics Jena GmbH trials

Trials by the same sponsor.

NCT05163730 — Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04959760 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abbott Rapid Diagnostics Jena GmbH
Last refreshed: 9 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04959760.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing